These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 19052976)

  • 61. [Correlation of NPM1, FLT3-ITD mutations with leukocyte count and myeloblasts percentage in AML patients with normal karyotype].
    Su L; Li W; Cui JW; Tan YH; Yang Y; Liu XL; Yu P; Hu RP; Wang LL; Gao SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):571-5. PubMed ID: 23815900
    [TBL] [Abstract][Full Text] [Related]  

  • 62. FLT3-ITD Mutations in Acute Myeloid Leukemia Patients in Northeast Thailand.
    Kumsaen P; Fucharoen G; Sirijerachai C; Chainansamit SO; Wisanuyothin N; Kuwatjanakul P; Wiangnon S
    Asian Pac J Cancer Prev; 2016; 17(9):4395-4399. PubMed ID: 27797250
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Impact of mutations in FLT3, PTPN11 and RAS genes on the overall survival of pediatric B cell precursor acute lymphoblastic leukemia in Brazil.
    Barbosa TC; Andrade FG; Lopes BA; de Andrade CF; Mansur MB; Emerenciano M; Pombo-de-Oliveira MS
    Leuk Lymphoma; 2014 Jul; 55(7):1501-9. PubMed ID: 24067137
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Impact of
    Picharski GL; Andrade DP; Fabro ALMR; Lenzi L; Tonin FS; Ribeiro RC; Figueiredo BC
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31492033
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treatment of infant leukemias: challenge and promise.
    Brown P
    Hematology Am Soc Hematol Educ Program; 2013; 2013():596-600. PubMed ID: 24319237
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cytogenetic Profile and
    Alkhayat N; Elborai Y; Al Sharif O; Al Shahrani M; Alsuhaibani O; Awad M; Elghezal H; Ben-Abdallah Bouhajar I; Alfaraj M; Al Mussaed E; Alabbas F; Elyamany G
    Clin Med Insights Oncol; 2017; 11():1179554917721710. PubMed ID: 28811744
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations.
    Singh H; Werner L; Deangelo D; Ballen K; Amrein P; Wadleigh M; Neuberg D; Fox E; Stone R; Attar E
    Am J Hematol; 2010 Dec; 85(12):956-7. PubMed ID: 20981678
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
    Tarlock K; Alonzo TA; Loken MR; Gerbing RB; Ries RE; Aplenc R; Sung L; Raimondi SC; Hirsch BA; Kahwash SB; McKenney A; Kolb EA; Gamis AS; Meshinchi S
    Clin Cancer Res; 2017 Jul; 23(14):3649-3656. PubMed ID: 28108543
    [No Abstract]   [Full Text] [Related]  

  • 69. Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia.
    Sanjuan-Pla A; Bueno C; Prieto C; Acha P; Stam RW; Marschalek R; Menéndez P
    Blood; 2015 Dec; 126(25):2676-85. PubMed ID: 26463423
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Demographic and prognostic factors of 455 patients with acute leukemia admitted to two referral hospitals in tehran-iran during ten years (2001-2011).
    Ayremlou P; Razavi SM; Solaymani-Dodaran M; Vakili M; Asadi-Lari M
    Iran J Cancer Prev; 2012; 5(3):157-63. PubMed ID: 25628835
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The evolution of clinical trials for infant acute lymphoblastic leukemia.
    Kotecha RS; Gottardo NG; Kees UR; Cole CH
    Blood Cancer J; 2014 Apr; 4(4):e200. PubMed ID: 24727996
    [TBL] [Abstract][Full Text] [Related]  

  • 72. RAS mutations in early age leukaemia modulated by NQO1 rs1800566 (C609T) are associated with second-hand smoking exposures.
    Andrade FG; Furtado-Silva JM; Gonçalves BA; Thuler LC; Barbosa TC; Emerenciano M; Siqueira A; Pombo-de-Oliveira MS;
    BMC Cancer; 2014 Feb; 14():133. PubMed ID: 24571676
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ligand-independent FLT3 activation does not cooperate with MLL-AF4 to immortalize/transform cord blood CD34+ cells.
    Montes R; Ayllón V; Prieto C; Bursen A; Prelle C; Romero-Moya D; Real PJ; Navarro-Montero O; Chillón C; Marschalek R; Bueno C; Menendez P
    Leukemia; 2014 Mar; 28(3):666-74. PubMed ID: 24240202
    [TBL] [Abstract][Full Text] [Related]  

  • 74. FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?
    Pemmaraju N; Kantarjian H; Ravandi F; Cortes J
    Cancer; 2011 Aug; 117(15):3293-304. PubMed ID: 21319142
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prognostic significance of FLT3 ITD and D835 mutations in AML patients.
    Sheikhha MH; Awan A; Tobal K; Liu Yin JA
    Hematol J; 2003; 4(1):41-6. PubMed ID: 12692519
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical significance of FLT3 in leukemia.
    Kiyoi H; Yanada M; Ozekia K
    Int J Hematol; 2005 Aug; 82(2):85-92. PubMed ID: 16146837
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical relevance of FLT3 gene abnormalities in Brazilian patients with infant leukemia.
    Emerenciano M; Menezes J; Vasquez ML; Zalcberg I; Thuler LC; Pombo-de-Oliveira MS;
    Leuk Lymphoma; 2008 Dec; 49(12):2291-7. PubMed ID: 19052976
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.